Amphastar Pharmaceuticals, Inc.

NASDAQ:AMPH

Drug Manufacturers - Specialty & Generic

Healthcare
$29.71 -1.60%

-$0.31 today

Market cap
$1.27B
Beta
0.90
P/E (TTM)
10.9
EPS (TTM)
$1.75
52W Low $16.65High $31.26

Volume 0.53M

Average 0.59M

AMPH Common Stock Repurchased

Cash spent buying back the company's own shares.

Amphastar Pharmaceuticals, Inc.NASDAQ: AMPH

Common Stock Repurchased · Q1 FY2026 · quarter ended Mar 2026

Common stock repurchased growth accelerates

Q1 FY2026 common stock repurchased of $29.49M (cash outflow) rose 168.1% year over year, ahead of the -59.6% change in trailing-twelve-month common stock repurchased. Sequentially, it rose 43.8% from the prior quarter. Over 3 fiscal years it compounded at +23.7% a year.

Context

  • Common stock repurchased amounted to 10.5% of revenue in FY2025, down 1.2 pp from a year earlier.
  • Common stock repurchased grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +168.1% holds above the trailing-twelve-month pace of -59.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$29.49M+43.8% QoQ
Last fiscal yearDec 2025
-$75.59M-11.6% YoY
LTMMar 2026
-$39.01M-59.6% YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+168.1%——
1 year-11.6%——
3-year CAGR+23.7%——
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
(75.59M) USD
Year-over-year change
+11.6%

Common Stock Repurchased vs competitors

How AMPH compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock repurchased is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -59.6% is the lowest of 6, against a peer median of +100.0%.
  • Common stock repurchased amounts to 5.4% of revenue for AMPH, versus a peer median of 0.0%.
AMPH Competitors
Common Stock Repurchased for AMPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VTRSViatris Inc.LTM Jun 2026$300.1M USD-14.4%—2.0%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$39.01M USD-59.6%+23.7%5.4%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$25.1M USD-58.2%+21.3%3.2%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$0 USD——0.0%
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹0 INR+100.0%—0.0%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$0 USD+100.0%—0.0%
BHCBausch Health Companies Inc.LTM Jun 2026$0 USD+100.0%—0.0%
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding AMPH) —+100.0%+21.3%0.0%

Competitors are the stored peer set for AMPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income63.3M91.39M137.55M159.52M98.09M
Depreciation & Amortization26.75M28.74M41.78M57.21M63.2M
Deferred Income Tax4.21M(15.75M)(13.74M)(17.87M)27.63M
Stock-Based Compensation18.69M17.86M20.24M24.37M27.28M
Change in Working Capital(1.92M)(32.18M)(24.21M)(14.55M)(65.97M)
Accounts Receivables(14.92M)(10.13M)(26.09M)(21.67M)(6.37M)
Inventory1.26M(11.75M)(1.72M)(48.8M)(21.06M)
Accounts Payables3.02M(736K)13.24M63.56M(4.56M)
Other Working Capital8.72M(9.56M)(9.64M)(7.64M)(33.98M)
Other Non-Cash Items(13.03M)(878K)21.89M4.71M5.89M
Operating Cash Flow97.99M89.18M183.5M213.39M156.12M
Capital Expenditures(27.46M)(24.03M)(38.17M)(41.04M)(34.88M)
Acquisitions (Net)0421K(506.41M)(129M)0
Purchases of Investments(17.38M)(35.76M)(144.56M)(76.79M)(119.13M)
Sales of Investments18.77M27.97M38.62M126.02M90.29M
Other Investing Activities(2.61M)(1.37M)1.39M(4.12M)(6.61M)
Investing Cash Flow(28.67M)(32.78M)(649.12M)(124.93M)(70.33M)
Debt Repayment32.1M(1.78M)526.34M10.17M5.99M
Common Stock Issued00002.86M
Common Stock Repurchased(28.87M)(39.91M)(58.14M)(85.46M)(75.59M)
Dividends Paid00000
Other Financing Activities(40.24M)15.25M(14.11M)(5.67M)(687K)
Financing Cash Flow(37.02M)(26.44M)454.09M(80.95M)(67.43M)
Effect of Forex Changes(223K)(220K)(282K)(190K)210K
Net Change in Cash32.08M29.75M(11.8M)7.31M18.57M
Free Cash Flow70.54M65.15M145.34M172.35M121.23M

Amphastar Pharmaceuticals, Inc.

NASDAQ:AMPH

Intrinsic Alpha fair value

Locked

Current Price

$29.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.